EMA: Draft Crizotinib hard capsules 200 mg and 250 mg product-specific bioequivalence guidance This document provides product-specific guidance on the demonstration of the bioequivalence of Crizotinib. Posted on the EMA website on 22 December 2016 editor2016-12-27T10:56:30+00:0027.12.2016|Regulatory Affairs, Training| Comparta esta información, escoja su plataforma FacebookTwitterLinkedInEmail
